BioNTech (NASDAQ:BNTX) Rating Increased to Neutral at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of BioNTech (NASDAQ:BNTX) from an underweight rating to a neutral rating in a research note released on Monday, MarketBeat reports. They currently have $125.00 target price on the stock, up from their previous target price of $91.00.

Other research analysts have also issued reports about the stock. TD Cowen dropped their price target on shares of BioNTech from $98.00 to $85.00 and set a hold rating on the stock in a research note on Tuesday, August 6th. HSBC upgraded BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. Hsbc Global Res raised BioNTech from a hold rating to a strong-buy rating in a report on Friday, August 2nd. HC Wainwright reaffirmed a buy rating and set a $113.00 price objective on shares of BioNTech in a report on Tuesday, August 27th. Finally, Jefferies Financial Group raised their target price on BioNTech from $90.00 to $96.00 and gave the company a hold rating in a report on Friday, September 13th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $120.31.

BioNTech Trading Down 7.3 %

Shares of BNTX stock opened at $115.62 on Monday. The company has a market capitalization of $27.49 billion, a P/E ratio of 231.24 and a beta of 0.23. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $89.02 and its two-hundred day moving average is $90.14. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s quarterly revenue was down 23.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.86) earnings per share. Equities analysts forecast that BioNTech will post -2.8 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA increased its position in shares of BioNTech by 2.8% during the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after acquiring an additional 131,490 shares during the last quarter. Harding Loevner LP bought a new position in BioNTech during the 4th quarter valued at $410,984,000. Capital World Investors grew its holdings in BioNTech by 0.5% during the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock worth $87,002,000 after acquiring an additional 4,369 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after purchasing an additional 24,426 shares during the last quarter. Finally, Candriam S.C.A. raised its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.